Logo Logo
Switch Language to German

Croci, Giorgio A.; Hoster, Eva; Beà, Sílvia; Veloza, Luis; Campo, Elias; Clasen-Linde, Erik; Goswami, Rashmi S.; Helgeland, Lars; Pileri, Stefano; Rymkiewicz, Grzegorz; Reinke, Sarah; Dreyling, Martin; Klapper, Wolfram; Clot, Guillem; Enjuanes, Anna; Scott, David W. and Cabeçadas, José (2020): Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11. In: Virchows Archiv: an international journal of pathology, Vol. 477, No. 2: pp. 259-267

Full text not available from 'Open Access LMU'.


Mantle cell lymphoma (MCL) shows a clinical aggressiveness that varies from patient to patient. Despite major advances in outcomes with current immunochemotherapy, the future development of therapies requires risk stratification to tailor therapy intensity. Within the group of reference pathologists for the ongoing trials of the European MCL Network, we performed a round robin test on a tissue microarray to evaluate the reproducibility in assessing the biomarkers of outcome in MCL. Cytological subtype, Ki67-index and expression of p53 and SOX11 were evaluated on 20 diagnostic tumour samples by eight participating labs independently. We demonstrate that the assessment of the proliferation index by counting the Ki67 positive cells as well as assessment of SOX11 and p53 expression status is reproducible between labs. For the most established prognostic biomarker, Ki67, the intra-class correlation coefficient was very good when assessed as a continuous parameter (0.87). The agreement was lower when the values were analysed in a dichotomized way applying the commonly used cutoff of 30% (kappa = 0.65, complete concordance of all labs in 13/20 (65%)). Cases with discrepant results between labs in the dichotomized analysis showed mean values close to the cutoff of 30%. Centralised scoring and digital image analysis revealed results in line with the scores from individual labs. All cases in our cohort were additionally assessed for gene expression signatures and of TP53 gene alterations. Given the good reproducibility when guidelines of assessment are applied, the biomarker studied in this inter-laboratory test presents potential candidates to be enhanced for risk-stratification in the future clinical trials.

Actions (login required)

View Item View Item